Literature DB >> 18368531

Internalization and desensitization of adenosine receptors.

Elisabeth C Klaasse1, Adriaan P Ijzerman, Willem J de Grip, Margot W Beukers.   

Abstract

Until now, more than 800 distinct G protein-coupled receptors (GPCRs) have been identified in the human genome. The four subtypes of the adenosine receptor (A(1), A(2A), A(2B) and A(3) receptor) belong to this large family of GPCRs that represent the most widely targeted pharmacological protein class. Since adenosine receptors are widespread throughout the body and involved in a variety of physiological processes and diseases, there is great interest in understanding how the different subtypes are regulated, as a basis for designing therapeutic drugs that either avoid or make use of this regulation. The major GPCR regulatory pathway involves phosphorylation of activated receptors by G protein-coupled receptor kinases (GRKs), a process that is followed by binding of arrestin proteins. This prevents receptors from activating downstream heterotrimeric G protein pathways, but at the same time allows activation of arrestin-dependent signalling pathways. Upon agonist treatment, adenosine receptor subtypes are differently regulated. For instance, the A(1)Rs are not (readily) phosphorylated and internalize slowly, showing a typical half-life of several hours, whereas the A(2A)R and A(2B)R undergo much faster downregulation, usually shorter than 1 h. The A(3)R is subject to even faster downregulation, often a matter of minutes. The fast desensitization of the A(3)R after agonist exposure may be therapeutically equivalent to antagonist occupancy of the receptor. This review describes the process of desensitization and internalization of the different adenosine subtypes in cell systems, tissues and in vivo studies. In addition, molecular mechanisms involved in adenosine receptor desensitization are discussed.

Entities:  

Year:  2007        PMID: 18368531      PMCID: PMC2245999          DOI: 10.1007/s11302-007-9086-7

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  97 in total

Review 1.  Structure and function of adenosine receptors and their genes.

Authors:  B B Fredholm; G Arslan; L Halldner; B Kull; G Schulte; W Wasserman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

2.  Role of adenosine A1 receptors in the modulation of dopamine D1 and adenosine A2A receptor signaling in the neostriatum.

Authors:  K Yabuuchi; M Kuroiwa; T Shuto; N Sotogaku; G L Snyder; H Higashi; M Tanaka; P Greengard; A Nishi
Journal:  Neuroscience       Date:  2006-06-05       Impact factor: 3.590

3.  Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids.

Authors:  Paulina Carriba; Oskar Ortiz; Kshitij Patkar; Zuzana Justinova; Jessica Stroik; Andrea Themann; Christa Müller; Anima S Woods; Bruce T Hope; Francisco Ciruela; Vicent Casadó; Enric I Canela; Carme Lluis; Steven R Goldberg; Rosario Moratalla; Rafael Franco; Sergi Ferré
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

4.  Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells.

Authors:  V Ramkumar; M E Olah; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1991-11       Impact factor: 4.436

5.  Arrestin specificity for G protein-coupled receptors in human airway smooth muscle.

Authors:  R B Penn; R M Pascual; Y M Kim; S J Mundell; V P Krymskaya; R A Panettieri; J L Benovic
Journal:  J Biol Chem       Date:  2001-06-20       Impact factor: 5.157

6.  Distinctive and synergistic signaling of human adenosine A2a and dopamine D2L receptors in CHO cells.

Authors:  Yuting Tang; Keith T Demarest
Journal:  J Recept Signal Transduct Res       Date:  2005       Impact factor: 2.092

7.  Heterotrimeric G protein-independent signaling of a G protein-coupled receptor. Direct binding of ARNO/cytohesin-2 to the carboxyl terminus of the A2A adenosine receptor is necessary for sustained activation of the ERK/MAP kinase pathway.

Authors:  Ingrid Gsandtner; Christoforos Charalambous; Eduard Stefan; Egon Ogris; Michael Freissmuth; Jürgen Zezula
Journal:  J Biol Chem       Date:  2005-07-18       Impact factor: 5.157

8.  Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.

Authors:  Luisa Minghetti; Anita Greco; Rosa Luisa Potenza; Antonella Pezzola; David Blum; Kadiombo Bantubungi; Patrizia Popoli
Journal:  J Neuropathol Exp Neurol       Date:  2007-05       Impact factor: 3.685

9.  Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization.

Authors:  C A Saura; J Mallol; E I Canela; C Lluis; R Franco
Journal:  J Biol Chem       Date:  1998-07-10       Impact factor: 5.157

10.  Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer.

Authors:  Meritxell Canals; Daniel Marcellino; Francesca Fanelli; Francisco Ciruela; Piero de Benedetti; Steven R Goldberg; Kim Neve; Kjell Fuxe; Luigi F Agnati; Amina S Woods; Sergi Ferré; Carme Lluis; Michel Bouvier; Rafael Franco
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

View more
  52 in total

Review 1.  G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Authors:  Kenneth A Jacobson; Ramachandran Balasubramanian; Francesca Deflorian; Zhan-Guo Gao
Journal:  Purinergic Signal       Date:  2012-02-29       Impact factor: 3.765

Review 2.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

3.  Chronic sleep restriction induces long-lasting changes in adenosine and noradrenaline receptor density in the rat brain.

Authors:  Youngsoo Kim; David Elmenhorst; Robert E Strecker; Andreas Bauer; Angela Weisshaupt; Franziska Wedekind; Tina Kroll; Robert W McCarley
Journal:  J Sleep Res       Date:  2015-04-21       Impact factor: 3.981

Review 4.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Intrahepatic expression of genes related to metabotropic receptors in chronic hepatitis.

Authors:  Andrzej Cieśla; Maciej Kuśmider; Agata Faron-Górecka; Marta Dziedzicka-Wasylewska; Monika Bociąga-Jasik; Danuta Owczarek; Irena Ciećko-Michalska; Dorota Cibor; Tomasz Mach
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

6.  Functional selectivity of adenosine A1 receptor ligands?

Authors:  Ellen V Langemeijer; Dennis Verzijl; Stefan J Dekker; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2012-09-28       Impact factor: 3.765

Review 7.  Pharmacological and therapeutic effects of A3 adenosine receptor agonists.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Bruce T Liang; Kenneth A Jacobson
Journal:  Drug Discov Today       Date:  2011-10-19       Impact factor: 7.851

8.  In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression.

Authors:  Akio Ohta; J Kjaergaard; S Sharma; M Mohsin; N Goel; M Madasu; E Fradkov; Akiko Ohta; M Sitkovsky
Journal:  Br J Pharmacol       Date:  2008-12-09       Impact factor: 8.739

9.  Adenosine mediated desensitization of cAMP signaling enhances T-cell responses.

Authors:  Ailian Yang; Ashley D Mucsi; Melanie D Desrosiers; Jiang-Fan Chen; Jürgen B Schnermann; Michael R Blackburn; Yan Shi
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

10.  Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor.

Authors:  Eszter Kozma; Elizabeth T Gizewski; Dilip K Tosh; Lucia Squarcialupi; John A Auchampach; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2013-01-31       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.